Report data from the registrational clinical trial for KarXT as adjunctive treatment
Delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 22 Dec 2023
- Due
- 31 Dec 2025
- Delivered
- April 2025
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“A registrational clinical trial is currently underway evaluating KarXT as adjunctive treatment with current standard of care agents for the treatment of schizophrenia, with data expected in 2025.”
What we found
Evidence strength A What the grades mean
The company reported data from the Phase III ARISE trial, which evaluated Cobenfy (KarXT) as an adjunctive treatment for schizophrenia, in April 2025, meeting the 2025 reporting deadline.
-
A Bristol Myers Squibb Co. 10-K filed 2026-02-11
“SchizophreniaApril 2025 Announced that the Phase III ARISE trial evaluating Cobenfy as an adjunctive treatment to atypical antipsychotics in adults with schizophrenia did not meet the threshold for statistical significance for the primary endpoint.” ✓ confirmed on the page
Market reaction: the shares moved +1.3% against the S&P 500 over the three sessions around the disclosure (10 Feb 2026 to 13 Feb 2026). What this measures
Checked 5 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- Data from registrational clinical trial for KarXT
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Bristol Myers Squibb Co.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2023-BMY-004812 · Corrections policy